Angiotensin converting enzyme activity in infancy is related to birth weight

J S Forsyth1, J Reilly, C G Fraser

  • 1Tayside Institute for Child Health, University of Dundee, Scotland, UK. j.stewart.forsyth@tuht.scot.nhs.uk

Insights

Infant angiotensin converting enzyme (ACE) activity is higher than maternal levels and inversely correlates with birth weight. This finding suggests a link between infant ACE activity, low birth weight, and future cardiovascular risk.

Area of Science:

  • Pediatric Cardiology
  • Biochemistry
  • Neonatology

Background:

  • Angiotensin converting enzyme (ACE) plays a crucial role in cardiovascular regulation.
  • Infant ACE activity and its determinants are not well understood.
  • ACE is implicated as a risk factor for cardiovascular disease.

Purpose of the Study:

  • To measure infant serum ACE activity from birth to three months.
  • To examine the relationship between infant ACE activity and feeding practices.
  • To investigate correlations between infant ACE activity and birth weight, gestation, and maternal factors.

Main Methods:

  • Prospective study of term infants.
  • Serum ACE activity measured in infants at birth, 1, and 3 months.
  • Maternal serum ACE measured at birth and 1-3 months postpartum.
  • Clinical and feeding data collected from parents and medical records.

Main Results:

  • Infant serum ACE activity was double maternal levels at all time points.
  • No significant difference in infant ACE activity between breast and formula-fed infants.
  • Significant negative correlation between infant ACE activity at 3 months and birth weight (r = -0.52, p < 0.001).
  • This correlation persisted after adjusting for birth weight z-scores, placental weight, and maternal age.

Conclusions:

  • Infant serum ACE activity is significantly higher than maternal levels.
  • Infant ACE activity is inversely correlated with birth weight, even after adjustments.
  • Elevated infant ACE activity may link low birth weight to later cardiovascular events.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Glomerular Filtration Rate and its Regulation01:28

Glomerular Filtration Rate and its Regulation

The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...